ArQule Initiates Phase I Cancer Trial
Posted on: Wednesday, 6 December 2006, 21:00 CST
ArQule has reported the enrollment and successful dosing of the first patient in a phase I clinical trial with the cancer therapy ARQ 171.
ArQule also updated progress in its other clinical programs. These include three phase II trials with the first-generation E2F-1 compound, ARQ 501, as monotherapy in leiomyosarcoma and head and neck cancer, and as combination therapy with gemcitabine in pancreatic cancer, as well as a phase I trial with ARQ 197, a small molecule inhibitor of the c-Met receptor tyrosine kinase. Swiss pharmaceutical company Roche has an option to ArQule's E2F-1 program in the field of cancer therapy.
The primary objective of the phase I trial is to determine the safety, tolerability and maximum tolerated dose of ARQ 171. Secondary objectives are to determine the pharmacokinetic profile and to assess the preliminary anti-tumor activity of the compound.
Source: Datamonitor
Related Articles
- Jennerex Completes Treatment for First Patient Cohort in Phase I Cancer Study
- Bionovo Announces Positive Developments in On-Going Phase 1/2 Cancer Drug Trial
- Array BioPharma Advances ErbB-2 Inhibitor, ARRY-380, into Phase 1 Cancer Patient Trial
- Enzon Starts Enrollment for Phase I Cancer Drug Trial
- Array BioPharma Advances P38 Inhibitor, ARRY-797, into Phase 1 Cancer Patient Trial
- Rexahn Announces Conclusion of Phase I Cancer Clinical Trial
- GammaCan Reports on Patient Enrollment in Phase II Clinical Trial; Company Pursues Toxicity and Efficacy Study of GCAN 101, Proprietary IVIg Therapy for Metastatic Cancers
- pSivida Announces BrachySil Cancer Therapy Achieves Primary Endpoint in Phase IIa Clinical Trials; Final Report Confirms BrachySil Safe and Well Tolerated
- Inovio Biomedical and University of Southampton Collaboration: Initiation of Phase I/II Clinical Trial in Patients With Recurrent Prostate Cancer
 |
 |
User Comments (0)
RSS Feeds